Exact Sciences Corporation (NASDAQ:EXAS) had its target price boosted by Roth Capital from $40.00 to $46.00 in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the stock. Vetr raised shares of Exact Sciences Corporation from a sell rating to a hold rating and set a $36.55 price objective for the company in a research report on Tuesday, July 25th. Lake Street Capital upped their target price on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a hold rating in a report on Wednesday. Cowen and Company upped their target price on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the stock an outperform rating in a report on Friday, May 5th. BTIG Research reaffirmed a buy rating and issued a $45.00 target price (up previously from $35.00) on shares of Exact Sciences Corporation in a report on Monday, July 17th. Finally, Craig Hallum reaffirmed a buy rating and issued a $46.00 target price (up previously from $41.00) on shares of Exact Sciences Corporation in a report on Wednesday. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $40.37.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) opened at 39.47 on Wednesday. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $42.18. The stock’s market cap is $4.70 billion. The firm’s 50 day moving average price is $36.19 and its 200 day moving average price is $27.48.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The firm had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. On average, analysts expect that Exact Sciences Corporation will post ($1.18) EPS for the current year.

WARNING: “Exact Sciences Corporation (EXAS) PT Raised to $46.00” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/exact-sciences-corporation-exas-pt-raised-to-46-00/1462832.html.

In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the sale, the senior vice president now owns 57,603 shares in the company, valued at approximately $2,028,201.63. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.00% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the company. Sheaff Brock Investment Advisors LLC raised its position in shares of Exact Sciences Corporation by 37.9% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 14,200 shares of the medical research company’s stock worth $335,000 after buying an additional 3,900 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in shares of Exact Sciences Corporation by 36.0% in the first quarter. Meadow Creek Investment Management LLC now owns 214,368 shares of the medical research company’s stock worth $5,063,000 after buying an additional 56,700 shares during the last quarter. Tyers Asset Management LLC raised its position in shares of Exact Sciences Corporation by 36.0% in the first quarter. Tyers Asset Management LLC now owns 122,496 shares of the medical research company’s stock worth $2,893,000 after buying an additional 32,400 shares during the last quarter. Elkfork Partners LLC raised its position in shares of Exact Sciences Corporation by 36.0% in the first quarter. Elkfork Partners LLC now owns 168,432 shares of the medical research company’s stock worth $3,978,000 after buying an additional 44,550 shares during the last quarter. Finally, C WorldWide Group Holding A S raised its position in shares of Exact Sciences Corporation by 9.2% in the first quarter. C WorldWide Group Holding A S now owns 191,154 shares of the medical research company’s stock worth $4,515,000 after buying an additional 16,154 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.